E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Time to Positivity of a Rapid Bedside Assay for Cardiac-Specific Troponin T Predicts Prognosis in Acute Coronary Syndromes: A Thrombolysis in Myocardial Infarction (TIMI) 11A Substudy
Elliott M. Antman,David B. Sacks,Nader Rifai,Carolyn H. McCabe,Christopher P. Cannon,Eugene Braunwald +5 more
TL;DR: A positive rapid assay for troponin T at presentation identifies those patients at risk for higher rates of adverse clinical events and longer, more complicated hospital stays.
Journal ArticleDOI
Comprehensive characterization of protein–protein interactions perturbed by disease mutations
Feixiong Cheng,Junfei Zhao,Yang Wang,Weiqiang Lu,Zehui Liu,Yadi Zhou,William R. Martin,Rui-Sheng Wang,Jin Huang,Tong Hao,Hong Yue,Jing Ma,Yuan Hou,Jessica A. Castrillon,Jiansong Fang,Jiansong Fang,Justin D. Lathia,Ruth A. Keri,Felice C. Lightstone,Elliott M. Antman,Raul Rabadan,David E. Hill,Charis Eng,Marc Vidal,Joseph Loscalzo +24 more
TL;DR: This human interactome network framework provides a powerful tool for prioritization of alleles with PPI-perturbing mutations to inform pathobiological mechanism- and genotype-based therapeutic discovery.
Journal ArticleDOI
Evaluation of High-Sensitivity Assays for Cardiac Troponin
TL;DR: In this issue of Clinical Chemistry, three reports provide valuable insights into possible new applications for more sensitive assays, as well as raise new questions that must be addressed in the course of evaluation of a new generation of high-sensitivity cardiac troponin assays.
Journal ArticleDOI
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
Giuseppe Boriani,Christian T. Ruff,Julia F Kuder,Minggao Shi,Hans Lanz,Howard Rutman,Michele Mercuri,Elliott M. Antman,Eugene Braunwald,Robert P. Giugliano +9 more
TL;DR: An increased BMI was independently associated with a lower risk of stroke/SEE, better survival, but increased risk of bleeding, and time in therapeutic range for warfarin improved significantly as BMI increased.
Journal ArticleDOI
Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38
Rebecca E. Wrishko,C. Steven Ernest,David S. Small,Ying G. Li,Govinda Weerakkody,Jeffrey R. Riesmeyer,William L. Macias,Shashank Rohatagi,Daniel E. Salazar,Elliott M. Antman,Stephen D. Wiviott,Eugene Braunwald,Lan Ni +12 more
TL;DR: The systemic exposure of prasugrel was not appreciably affected by body mass index, gender, diabetes, smoking, and renal impairment, and the PK of Pras‐AM was adequately described by a multicompartmental model and consistent with results from previous studies.